Question 1

What conditions is Metex Pen used to treat?

Accepted Answer

Metex Pen contains methotrexate, which is prescribed for rheumatoid arthritis, moderate to severe plaque psoriasis, certain hematologic cancers such as acute lymphoblastic leukemia and non‑Hodgkin lymphoma, and for medical management of ectopic pregnancy. The specific indication depends on the patient’s diagnosis and the prescribing clinician’s assessment.

Question 2

How does methotrexate work in the body?

Accepted Answer

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate needed for purine and pyrimidine synthesis. This hampers DNA, RNA and protein production, reducing the proliferation of rapidly dividing cells, including immune cells and malignant cells, thereby providing immunosuppressive and anticancer effects.

Question 3

What is the usual dose of Metex Pen?

Accepted Answer

The dose of Metex Pen is individualized by the treating physician based on the patient’s condition, weight, renal function and response to therapy. The prescriber determines the exact amount, frequency and duration of treatment, and patients should follow the written prescription without alteration.

Question 4

Is Metex Pen safe to use during pregnancy or while breastfeeding?

Accepted Answer

Methotrexate is classified as Pregnancy Category X because it is known to cause fetal harm and is contraindicated in pregnancy. It is also excreted in breast milk and may affect the infant. Women of child‑bearing potential must use effective contraception, and breastfeeding is not recommended while on therapy.

Question 5

How do I order Metex Pen from GNH USA?

Accepted Answer

To request Metex Pen, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Question 6

How does Metex Pen compare with other immunosuppressants?

Accepted Answer

Methotrexate, the active ingredient in Metex Pen, is an antimetabolite presented as a pre‑filled pen for subcutaneous injection use. It treats rheumatoid arthritis, psoriasis, certain cancers and ectopic pregnancy in appropriate patients.

GNH USA supplies Metex Pen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Question 7

What are the storage requirements for Metex Pen?

Accepted Answer

Metex Pen should be stored in a refrigerator at 2‑8 °C (36‑46 °F). Keep the pen in its original packaging, protect it from light, and avoid freezing or shaking. If a short period at room temperature is unavoidable, follow the manufacturer’s guidance on maximum exposure time.

Question 8

How is Metex Pen administered?

Accepted Answer

Metex Pen is a pre‑filled, single‑use pen designed for subcutaneous injection. The patient or healthcare professional selects the prescribed dose, removes the needle guard, and injects the medication into the subcutaneous tissue of the thigh, abdomen or upper arm, rotating sites with each injection to reduce local irritation.

Question 9

What are the most serious risks associated with Metex Pen?

Accepted Answer

The most serious risks include severe liver toxicity, bone‑marrow suppression leading to pancytopenia, pulmonary fibrosis or interstitial pneumonitis, acute renal failure, and life‑threatening infections. Patients should be monitored regularly for liver enzymes, blood counts and renal function, and any signs of respiratory distress or infection require immediate medical attention.

Question 10

Who should not use Metex Pen?

Accepted Answer

Metex Pen is contraindicated in pregnant or breastfeeding women, patients with known hypersensitivity to methotrexate, those with severe hepatic or renal impairment, and individuals with active, uncontrolled infections. It should also be avoided in patients receiving live vaccines or in combination with other drugs that markedly increase methotrexate toxicity without close supervision.